The Delaware Flip: How European Biotechs Win US VC Funding

The short answer: A Delaware flip moves a European biotech under a new US (Delaware) parent company through a share exchange, so US VCs can invest in a structure they know. It makes sense when a US lead investor is in play and your clinical, commercial or exit path runs through the US. It does not fix a weak data package, and it must be planned with legal and tax counsel in every jurisdiction involved.

A Delaware flip for a European biotech is a structural decision, not a fundraising tactic. Done at the right moment, it removes friction with US investors. Done too early or too late, it adds tax exposure, cost and months of delay. This guide covers the mechanics, the trade-offs and what US investors actually test before they write a check.

Why are European biotech founders looking at US VC in 2026?

The capital gap is structural. When the European Life Sciences Coalition launched in February 2026, it reported that Europe accounts for just 7% of global life-sciences venture capital, versus 63% for the US and 14% for China. It also noted that 66 of 67 EU biotech companies that went public over the past six years listed outside the EU.

European money is growing. Jeito Capital closed Jeito II at €1 billion (about $1.2 billion) in April 2026, and Kurma Partners closed its €215 million Biofund IV the same month. PitchBook reported in July 2026 that European biotech VC had reached roughly €800 million year to date, on pace for a record, with large rounds such as Nuclidium's CHF 105 million (about $130 million) Series B and RQ Bio's $115 million Series A.

But PitchBook also reported that US biotech startup fundraising this year is about triple Europe's. EY's 2026 Biotech Beyond Borders report shows capital concentrating in late-stage rounds ($10 billion across 254 late-stage rounds in 2025) while early-stage funding fell. For a European company planning a large Series A or B, US investors are often needed to complete the round.

What is a Delaware flip, exactly?

In the standard structure described by firms such as Fenwick, Orrick and Pillsbury:

Employee option plans are typically replaced with topco equivalents. The operating company, its team and often its grants stay in Europe.

When does a flip make sense, and when does it not?

Pillsbury's guidance is blunt: absent compelling investor demand or US expansion needs, a flip adds complexity and cost without clear benefit. Orrick notes many founders wait until a US fund explicitly asks for it. Our view at PXM: prepare the plan early, execute when a credible US lead is engaged.

What tax, IP and legal issues should you plan for?

This section is a high-level map, not advice. Every flip needs corporate and tax counsel in each relevant jurisdiction, engaged before you sign a term sheet.

What do US VCs look for in diligence?

The structure gets you in the room. The asset closes the round. US investors consistently test four things:

A credible FDA path. Pre-IND meeting plan or minutes, clear indication and endpoints, and a view on how EU data supports a US filing. See PXM's FDA regulatory affairs work.

CMC that scales. Process, analytical methods, CDMO strategy and supply for US trials. CMC gaps are a common reason rounds slip.

A US-facing team. Not necessarily a relocated CEO, but named senior people who have run FDA interactions, US trials or US BD. PXM's Operate practice embeds senior operators as fractional heads of regulatory, CMC, clinical and BD to close that gap.

A data package that survives scrutiny. Reproducible preclinical data, a clean data room, and a milestone plan that maps the round to a value-inflection event.

US-VC readiness checklist

• US lead or co-lead investors identified and engaged
• Flip decision memo prepared with legal and tax counsel in each jurisdiction
• Cap table clean, with option plan mapped to a US-style equivalent
• IP chain of title documented; IP location decided
• Grant and incentive conditions reviewed for change-of-control or holding-period clauses
• FDA strategy written: indication, pre-IND plan, EU-to-US data bridge
• CMC plan: process, analytics, CDMO and US clinical supply
• US-experienced regulatory, clinical and BD leadership named (full-time or fractional)
• Data room organized to US diligence standards
• Use of proceeds tied to a specific value-inflection milestone

FAQ

Do all US VCs require a Delaware flip?
No. Many prefer it, and some require it as a condition of leading. Others will invest in a European entity, especially alongside strong EU co-investors. Ask early.

When is the best time to do a Delaware flip?
Fenwick notes that earlier is simpler, since more shareholders and history add complexity. In practice, most companies execute alongside a round with a committed US lead, with planning done months ahead.

Can we keep EU grants after flipping?
Often yes, since the European subsidiary usually remains the operating and grant-holding entity. Eligibility and change-of-control terms vary by program, so review each one before the flip.

Does a flip mean moving the company to the US?
No. A flip changes the parent company's legal home. R&D, staff and operations can stay in Europe, though governance must be structured to manage tax residency.

Ready for US investors?

PXM works with European biotech companies on the structure, regulatory path and operating team US VCs expect, and prepares companies for financing through its Transact practice. Learn more on our For Companies page.

Show PXM what you are building

Sources